Table 1.
Independent external validation of the 8th edition staging of HPV-related oropharyngeal cancer.
| 5-y OS by 8th edition TNM stage | |||||||
|---|---|---|---|---|---|---|---|
| Author | Year of publication | Patients | Primary treatment | I | II | III | IV |
| O'Sullivan [6] | 2016 | 1907 | S: 34; RT: 1873 | 85% | 78% | 53% | NA |
|
| |||||||
| Haughey [7] | 2016 | 704 | S: 704 | 90% | 84% | 48% | NA |
|
| |||||||
| Cramer [8] | 2017 | 15116 | S: 6465; RT: 7841; CHT: 276 | 87.4%∗ | 76.6%∗ | 63.1%∗ | 20.7%∗ |
|
| |||||||
| Malm [9] | 2017 | 435 | S: 166; RT: 269 | 92.3% | 87.2% | 73.6% | 40.0% |
|
| |||||||
| Porceddu [10] | 2017 | 279 | RT: 279 | 93.6% | 81.9% | 69.1% | NA |
international collaboration on oropharyngeal cancer network for staging (ICON-S) study
∗4-year overall survival
5-y OS: 5-year overall survival; S: surgery; RT: radiotherapy; CHT: chemotherapy; NA: not applicable